Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

The Fujian Provincial Medical Security Bureau has implemented the “Ten Measures to Support the Innovative Development of the Biomedical Industry”, establishing a comprehensive policy framework designed to leverage medical insurance policies as strategic catalysts for high-quality biomedical sector development. The measures, effective immediately from June 26, 2026, introduce groundbreaking reforms across online listing, pricing mechanisms, medical insurance payments, and multi-tiered coverage systems.

Policy Framework Overview

Accelerated Market Access Provisions

• Streamlined Listing Process: Innovative pharmaceutical and medical device products eligible for dynamic application with centralized review
• Rapid Time-to-Market: Online listing completion within 15 working days after centralized acceptance
• Green Channel Establishment: Priority processing for innovative projects addressing major disease treatment gaps
• National Alignment: Accelerated harmonization with national medical service pricing project guidelines
• Administrative Efficiency: Reduced bureaucratic barriers through digital-first procurement mechanisms

Innovative Pricing Framework

Medical Insurance Payment Reforms

• Catalog Management Optimization: Enhanced flexibility in managing insurance drug catalogs
• Commercial Insurance Integration: Innovative drugs in commercial health insurance catalogs receive preferential treatment:
• Excluded from basic medical insurance out-of-pocket rate indicators
• Exempt from VBP winner substitutable product monitoring scope
• Outside DRG/DIP payment constraint mechanisms
• Dual-Channel System Enhancement: Improved management of dual-channel drug distribution and electronic prescription circulation
• Special-Case Payment Support: Appropriate use of innovative medicines eligible for fee-for-service payment through special-case review processes

Multi-Tiered Coverage Innovation

• Insurance Integration: Promotion of customized commercial medical insurance products integrated with basic medical insurance
• Simultaneous Settlement: Exploration of real-time dual settlement mechanisms for basic and commercial insurance
• Financial Burden Reduction: Direct settlement of pharmaceutical and device payments to suppliers to improve cash flow
• Value-Based Assessment: Advancement of real-world comprehensive value assessment research to inform coverage decisions

Strategic Market Implications

Competitive Advantage for Fujian

• First-Mover Status: Among most comprehensive provincial innovation support frameworks in China
• Investment Attraction: Enhanced appeal for biomedical R&D investment and manufacturing establishment
• Talent Retention: Improved ecosystem for biomedical professionals and researchers
• Industry Clustering: Potential to establish Fujian as preferred location for innovative biomedical companies
• Policy Leadership: Demonstrates provincial commitment to becoming national model for biomedical innovation support

Implementation Monitoring & Success Metrics

• Listing Efficiency: 15-working-day target compliance rate
• Pricing Outcomes: Premium realization for highly innovative products
• Coverage Expansion: Growth in innovative drug utilization rates
• Financial Impact: Reduction in supplier payment delays and improved cash conversion cycles
• Patient Access: Measurable improvement in time-to-treatment for innovative therapies

Forward‑Looking Statements
This brief contains forward-looking statements regarding policy implementation, market opportunities, and regulatory reforms. Actual outcomes may differ due to risks including implementation execution, stakeholder adoption rates, and evolving regulatory interpretations.-Fineline Info & Tech